- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

It could be you! Award for innovation is launched

The drug industry’s public stock remains undeservedly low. But you could help change it. Recognising, rewarding and promoting the industry’s strengths may just be a vital ingredient in rebuilding public trust.The 2008 Prix Galien Awards provide that opportunity.Has your drug got what it takes to win a coveted Prix Galien medal?

Has the drug you’re working with been launched in the UK in the past 18 months? Has it made a demonstrable difference to health outcomes in the UK?

Or are you about to work on a product that you expect will be granted a new indication by March 2008? And do you anticipate it will make a positive societal and economical impact on the UK market?

Crucially, would your product withstand robust scrutiny from some of the medical profession’s most eminent experts?

If you can answer ‘yes’ to all of these questions then perhaps your product should be considered for one of the global industry’s most prestigious prizes, the Prix Galien Award for Innovation.

The winner will demonstrate an ability to make a genuine difference to patient welfare in the UK. Competition will be fierce, but who knows? It could be you.

What is Prix Galien?

Prix Galien rewards outstanding achievement in the field of pharmaceutical research and development. It remains the only competition of its kind that is completely independent of the industry, and is judged by an esteemed panel of some of its toughest customers, headed by NICE chairman Professor Sir Michael Rawlins.

The Prix Galien Advisory Board looks for the product that it believes will make the most significant contribution to patient care in the UK, focusing heavily on innovation.

Entry criteria

  • Has your product been launched in the UK since January 2006?
  • Or do you expect it to be granted a new indication by March 2008?
  • Has it made a demonstrable difference to health outcomes in the UK?
  • Do you anticipate it will make a positive societal and economical impact on the UK market?
  • Does/can your product demonstrate an ability to make a genuine difference to patient welfare in the UK?
  • Would it withstand robust scrutiny from some of the medical profession’s most eminent experts?

Submissions will look in detail at the following:

  • Product concept – why the product was developed, screening techniques, complexity of development.
  • Clinical evaluation – trial design, data and analysis.
  • Economic impact – costeffectiveness analyses, predicted budgetary impact, societal impact.
  • Population health impact – market size, patient impact, predicted health gains.

Entries are now being invited for the 2007/08 award, which will take place at the Houses of Parliament next September.

WG Consulting, which owns the UK franchise of this internationally-renowned award, is currently seeking submissions for products that either launched or will be granted a new indication in the UK market in the period January 2006 to March 2008.

Why enter?

Entering the Prix Galien gives pharmaceutical companies a unique opportunity to subject their products to the direct scrutiny of a panel of key opinion leaders from across the world of science and medicine – itself a highly valuable exercise. In addition, winning such a prestigious prize is not only motivational internally, but, crucially, can significantly enhance a company’s external reputation. Last year, Rotarix (GSK) and Xolair (Novartis) shared the main award, with Myozyme (Genzyme) picking up a special Prix Galien medal as an orphan drug.

Previous winners include Prevenar and Meningitec (Wyeth) Glivec (Novartis), Herceptin, Fuzeon and Invirase (Roche),Viagra (Pfizer), Singulair (MSD), Zyprexa (Lilly), Zovirax (GSK), and Adalat (Bayer).

What to do next? – Deadline for registration is 31st January 2008. Final submissions should be made by 31st March 2008. For further details visit www.wg-group.co.uk and click on ‘Prix Galien’ or email prixgalien@westawaygillis.co.uk
- Advertisement -

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription